PDCD1 and hepatocellular carcinoma: Sorafenib and lenvatinib administration are recommended first line treatments for advanced stage HCC.[5–7] In 2017, the Food and Drug Administration approved a novel programmed cell death 1 (PD-1) checkpoint inhibitor known as nivolumab.